Virologica Sinica

, Volume 23, Issue 6, pp 438–448 | Cite as

Pathogenetic consequences of cytomegalovirus-host co-evolution

  • Gerardo Abenes
  • Fenyong LiuEmail author


Co-evolution has been shown to result in an adaptive reciprocal modification in the respective behaviors of interacting populations over time. In the case of host-parasite co-evolution, the adaptive behavior is most evident from the reciprocal change in fitness of host and parasite-manifested in terms of pathogen survival versus host resistance. Cytomegaloviruses and their hosts represent a pairing of populations that has co-evolved over hundreds of years. This review explores the pathogenetic consequences emerging from the behavioral changes caused by co-evolutionary forces on the virus and its host.

Key words

Cytomegalovirus Co-evolution Pathogenesis 

CLC number



Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Adler S P, Marshall B. 2007. Cytomegalovirus infections. Pediatr Rev, 28: 92–100.PubMedGoogle Scholar
  2. 2.
    Ahn K, Angulo A, Ghazal P, et al. 1996. Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. Proc Natl Acad Sci USA, 93: 10990–10995.PubMedGoogle Scholar
  3. 3.
    Ahn K, Gruhler A, Galocha B, et al. 1997. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity, 6: 613–621.PubMedGoogle Scholar
  4. 4.
    Arase H, Mocarski E S, Campbell A E, et al. 2002. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science, 296: 1323–1326.PubMedGoogle Scholar
  5. 5.
    Askin D F. 2004. Intrauterine infections. Neonatal Netw, 23: 23–30.PubMedGoogle Scholar
  6. 6.
    Atreya I, Atreya R, Neurath M F. 2008. NF-kappaB in inflammatory bowel disease. J Intern Med, 263:591–596.PubMedGoogle Scholar
  7. 7.
    Bale J F. 2002. Congenital infections. Neurol Clin, 20:1039–1060.PubMedGoogle Scholar
  8. 8.
    Bason C, Corrocher R, Lunardi C, et al. 2003. Interaction of antibodies against cytomegalovirus with heat-shock protein 60 in pathogenesis of atherosclerosis. Lancet, 362: 1971–1977.PubMedGoogle Scholar
  9. 9.
    Basta S, Bennink J R. 2003. A survival game of hide and seek: cytomegaloviruses and MHC class I antigen presentation pathways. Viral Immunol, 16: 231–242.PubMedGoogle Scholar
  10. 10.
    Bauer D, Tampe R. 2002. Herpes viral proteins blocking the transporter associated with antigen processing TAP—from genes to function and structure. Curr Top Microbiol Immunol, 269: 87–99.PubMedGoogle Scholar
  11. 11.
    Bego M G, St Jeor S. 2006. Human cytomegalovirus infection of cells of hematopoietic origin: HCMV-induced immunosuppression, immune evasion, and latency. Exp Hematol, 34: 555–570.PubMedGoogle Scholar
  12. 12.
    Beisser P S, Goh C S, Cohen F E, et al. 2002. Viral chemokine receptors and chemokines in human cytomegalovirus trafficking and interaction with the immune system. CMV chemokine receptors. Curr Top Microbiol Immunol, 269: 203–34.PubMedGoogle Scholar
  13. 13.
    Bentz G L, Yurochko A D. 2008. Human CMV infection of endothelial cells induces an angiogenic response through viral binding to EGF receptor and beta1 and beta3 integrins. Proc Natl Acad Sci USA, 105: 5531–5536.PubMedGoogle Scholar
  14. 14.
    Boomker J M, de Jong E K, de Leij L F, et al. 2006. Chemokine scavenging by the human cytomegalovirus chemokine decoy receptor US28 does not inhibit monocyte adherence to activated endothelium. Antiviral Res, 69: 124–127.PubMedGoogle Scholar
  15. 15.
    Boomker J M, van Luyn M J, The T H, et al. 2005. US28 actions in HCMV infection: lessons from a versatile hijacker. Rev Med Virol, 15: 269–282.PubMedGoogle Scholar
  16. 16.
    Braud V M, Tomasec P, Wilkinson G W. 2002. Viral evasion of natural killer cells during human cytomegalovirus infection. Curr Top Microbiol Immunol, 269: 117–129.PubMedGoogle Scholar
  17. 17.
    Bryant P, Morley C, Garland S, et al. 2002. Cytomegalovirus transmission from breast milk in premature babies: does it matter? Arch Dis Child Fetal Neonatal Ed, 87: F75–77.PubMedGoogle Scholar
  18. 18.
    Candore G, Balistreri C R, Colonna-Romano G, et al. 2008. Immunosenescence and anti-immunosenescence therapies: the case of probiotics. Rejuvenation Res, 11: 425–432.PubMedGoogle Scholar
  19. 19.
    Chalupny N J, Rein-Weston A, Dosch S, et al. 2006. Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Biochem Biophys Res Commun, 346: 175–181.PubMedGoogle Scholar
  20. 20.
    Chang M, Pan M R, Chen D Y, et al. 2006. Human cytomegalovirus pp65 lower matrix protein: a humoral immunogen for systemic lupus erythematosus patients and autoantibody accelerator for NZB/W F1 mice. Clin Exp Immunol, 143: 167–179.PubMedGoogle Scholar
  21. 21.
    Chapman T L, Heikeman A P, Bjorkman P J. 1999. The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18. Immunity, 11: 603–613.PubMedGoogle Scholar
  22. 22.
    Cosman D, Mullberg J, Sutherland C L, et al. 2001. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity, 14: 123–133.PubMedGoogle Scholar
  23. 23.
    Criscuoli V, Rizzuto M R, Cottone M. 2006. Cytomega-lovirus and inflammatory bowel disease: is there a link? World J Gastroenterol, 12: 4813–4818.PubMedGoogle Scholar
  24. 24.
    Damato E G, Winnen C W. 2002. Cytomegalovirus infection: perinatal implications. J Obstet Gynecol Neonatal Nurs, 31: 86–92.PubMedGoogle Scholar
  25. 25.
    Davison A J, Dolan A, Akter P, et al. 2003. The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome. J Gen Virol, 84: 17–28.PubMedGoogle Scholar
  26. 26.
    DeFilippis V R. 2007. Induction and evasion of the type I interferon response by cytomegaloviruses. Adv Exp Med Biol, 598:309–24.PubMedGoogle Scholar
  27. 27.
    Diaz F, Urkijo J C, Mendoza F, et al. 2006. Systemic lupus erythematosus associated with acute cytomegalovirus infection. J Clin Rheumatol, 12: 263–264.PubMedGoogle Scholar
  28. 28.
    Dimitroulia E, Spanakis N, Konstantinidou A E, et al. 2006. Frequent detection of cytomegalovirus in the intestine of patients with inflammatory bowel disease. Inflamm Bowel Dis, 12: 879–884.PubMedGoogle Scholar
  29. 29.
    Dugan G E, Hewitt E W. 2008. Structural and Functional Dissection of the Human Cytomegalovirus Immune Evasion Protein US6. J Virol, 82: 3271–3282.PubMedGoogle Scholar
  30. 30.
    Dunn C, Chalupny N J, Sutherland C L, et al. 2003. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J Exp Med, 197: 1427–1439.PubMedGoogle Scholar
  31. 31.
    Dunn W, Chou C, Li H, et al. 2003. Functional profiling of a human cytomegalovirus genome. Proc Natl Acad Sci USA, 100: 14223–14228.PubMedGoogle Scholar
  32. 32.
    Editorial Comments. 2004. Cytomegalovirus. Am J Transplant, 4Suppl 10:51–58.Google Scholar
  33. 33.
    Emery V C. 2001. Cytomegalovirus and the aging population. Drugs Aging, 18: 927–933.PubMedGoogle Scholar
  34. 34.
    Emery V C. 2001. Investigation of CMV disease in immunocompromised patients. J Clin Pathol, 54: 84–88.PubMedGoogle Scholar
  35. 35.
    Franceschi C. 2007. Inflammaging as a major characteristic of old people: can it be prevented or cured? Nutr Rev, 65: S173–176.PubMedGoogle Scholar
  36. 36.
    Franceschi C, Bonafe M. 2003. Centenarians as a model for healthy aging. Biochem Soc Trans 31: 457–61.PubMedGoogle Scholar
  37. 37.
    Froberg M K. 2004. Review: CMV escapes! Ann Clin Lab Sci, 34: 123–130.PubMedGoogle Scholar
  38. 38.
    Gewurz B E, Gaudet R, Tortorella D, et al. 2001. Antigen presentation subverted: Structure of the human cytomegalovirus protein US2 bound to the class I molecule HLA-A2. Proc Natl Acad Sci USA, 98: 6794–6799.PubMedGoogle Scholar
  39. 39.
    Giunta S. 2006. Is inflammaging an auto[innate] immunity subclinical syndrome? Immun Ageing, 3: 12.PubMedGoogle Scholar
  40. 40.
    Gold E, Nankervis G A. 1976. Cytomegalovirus. In: Viral infections of humans: epidemiology and control (Evans A S ed.), Plenum Press: New York, p 143–161.Google Scholar
  41. 41.
    Goldmacher V S. 2005. Cell death suppression by cytomegaloviruses. Apoptosis, 10: 251–265.PubMedGoogle Scholar
  42. 42.
    Goldmacher V S. 2002. vMIA, a viral inhibitor of apoptosis targeting mitochondria. Biochimie, 84: 177–185.PubMedGoogle Scholar
  43. 43.
    Hengel H, Koopmann J O, Flohr T, et al. 1997. A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity, 6: 623–632.PubMedGoogle Scholar
  44. 44.
    Hommes D W, Sterringa G, van Deventer S J, et al. 2004. The pathogenicity of cytomegalovirus in inflammatory bowel disease: a systematic review and evidence-based recommendations for future research. Inflamm Bowel Dis, 10: 245–250.PubMedGoogle Scholar
  45. 45.
    Hooper M, Kallas E G, Coffin D, et al. 1999. Cytomegalovirus seropositivity is associated with the expansion of CD4+CD28 and CD8+CD28 T cells in rheumatoid arthritis. J Rheumatol, 26: 1452–1457.PubMedGoogle Scholar
  46. 46.
    Hrycek A, Kusmierz D, Mazurek U, et al. 2005. Human cytomegalovirus in patients with systemic lupus erythematosus. Autoimmunity, 38: 487–491.PubMedGoogle Scholar
  47. 47.
    Hussein K, Hayek T, Yassin K, et al. 2006. Acute cytomegalovirus infection associated with the onset of inflammatory bowel disease. Am J Med Sci, 331: 40–43.PubMedGoogle Scholar
  48. 48.
    Jarvis M A, Borton J A, Keech A M, et al. 2006. Human cytomegalovirus attenuates interleukin-1beta and tumor necrosis factor alpha proinflammatory signaling by inhibition of NF-kappaB activation. J Virol, 80: 5588–5598.PubMedGoogle Scholar
  49. 49.
    Jarvis M A, Nelson J A. 2002. Human cytomegalovirus persistence and latency in endothelial cells and macrophages. Curr Opin Microbiol, 5:403–407.PubMedGoogle Scholar
  50. 50.
    Jarvis M A, Nelson J A. 2002. Mechanisms of human cytomegalovirus persistence and latency. Front Biosci, 7: 1575–1582.Google Scholar
  51. 51.
    Jenkins C, Abendroth A, Slobedman B. 2004. A novel viral transcript with homology to human interleukin-10 is expressed during latent human cytomegalovirus infection. J Virol, 78: 1440–1447.PubMedGoogle Scholar
  52. 52.
    Johnson D C, Hegde N R. 2002. Inhibition of the MHC class II antigen presentation pathway by human cytomegalovirus. Curr Top Microbiol Immunol, 269: 101–115.PubMedGoogle Scholar
  53. 53.
    Jones T R, Wiertz E J, Sun L, et al. 1996. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc Natl Acad Sci USA, 93: 11327–11333.PubMedGoogle Scholar
  54. 54.
    Jurak I, Brune W. 2006. Induction of apoptosis limits cytomegalovirus cross-species infection. Embo J, 25: 2634–2642.PubMedGoogle Scholar
  55. 55.
    Kanapeckiene V, Kalibatas J, Redaitiene E, et al. 2007. The association between cytomegalovirus infection and aging process. Medicina (Kaunas), 43: 419–424.Google Scholar
  56. 56.
    Kavanagh D G, Hill A B. 2001. Evasion of cytotoxic T lymphocytes by murine cytomegalovirus. Semin Immunol, 13: 19–26.PubMedGoogle Scholar
  57. 57.
    Kerrey B T, Morrow A, Geraghty S, et al. 2006. Breast milk as a source for acquisition of cytomegalovirus (HCMV) in a premature infant with sepsis syndrome: detection by real-time PCR. J Clin Virol, 35: 313–316.PubMedGoogle Scholar
  58. 58.
    Khan N. 2007. The immunological burden of human cytomegalovirus infection. Arch Immunol Ther Exp (Warsz), 55: 299–308.Google Scholar
  59. 59.
    Khan N, Hislop A, Gudgeon N, et al. 2004. Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the response to a coresident EBV infection. J Immunol, 173: 7481–7489.PubMedGoogle Scholar
  60. 60.
    Khan N, Shariff N, Cobbold M, et al. 2002. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol, 169: 1984–1992.PubMedGoogle Scholar
  61. 61.
    Khoshnevis M, Tyring S K. 2002. Cytomegalovirus infections. Dermatol Clin, 20: 291–299, vii.PubMedGoogle Scholar
  62. 62.
    Kinney J S, Onorato I M, Stewart J A, et al. 1985. Cytomegaloviral infection and disease. J Infect Dis, 151: 772–774.PubMedGoogle Scholar
  63. 63.
    Kojima T, Watanabe T, Hata K, et al. 2006. Cytomegalovirus infection in ulcerative colitis. Scand J Gastroenterol, 41: 706–711.PubMedGoogle Scholar
  64. 64.
    Koutouzov S, Jeronimo A L, Campos H, et al. 2004. Nucleosomes in the pathogenesis of systemic lupus erythematosus. Rheum Dis Clin North Am, 30: 529–558, ix.PubMedGoogle Scholar
  65. 65.
    Krmpotic A, Bubic I, Polic B, et al. 2003. Pathogenesis of murine cytomegalovirus infection. Microbes Infect, 5: 1263–1277.PubMedGoogle Scholar
  66. 66.
    Landolfo S, Gariglio M, Gribaudo G, et al. 2003. The human cytomegalovirus. Pharmacol Ther, 98: 269–297.PubMedGoogle Scholar
  67. 67.
    Lehner P J, Karttunen J T, Wilkinson G W, et al. 1997. The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation. Proc Natl Acad Sci USA, 94: 6904–6909.PubMedGoogle Scholar
  68. 68.
    Lenac T, Arapovic J, Traven L, et al. 2008. Murine cytomegalovirus regulation of NKG2D ligands. Med Microbiol Immunol, 197: 159–166.PubMedGoogle Scholar
  69. 69.
    Lin A, Xu H, Yan W. 2007. Modulation of HLA expression in human cytomegalovirus immune evasion. Cell Mol Immunol, 4: 91–98.PubMedGoogle Scholar
  70. 70.
    Lodoen M B, Abenes G, Umamoto S, et al. 2004. The cytomegalovirus m155 gene product subverts natural killer cell antiviral protection by disruption of H60-NKG2D interactions. J Exp Med, 200: 1075–1081.PubMedGoogle Scholar
  71. 71.
    Loenen W A, Bruggeman C A, Wiertz E J. 2001. Immune evasion by human cytomegalovirus: lessons in immunology and cell biology. Semin Immunol, 13: 41–49.PubMedGoogle Scholar
  72. 72.
    Lunardi C, Bason C, Corrocher R, et al. 2005. Induction of endothelial cell damage by hCMV molecular mimicry. Trends Immunol, 26: 19–24.PubMedGoogle Scholar
  73. 73.
    Lunardi C, Bason C, Navone R, et al. 2000. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med, 6: 1183–1186.PubMedGoogle Scholar
  74. 74.
    Lunardi C, Dolcino M, Peterlana D, et al. 2006. Antibodies against human cytomegalovirus in the pathogenesis of systemic sclerosis: a gene array approach. PLoS Med, 3: e2.PubMedGoogle Scholar
  75. 75.
    Lunardi C, Dolcino M, Peterlana D, et al. 2007. Endothelial cells’ activation and apoptosis induced by a subset of antibodies against human cytomegalovirus: relevance to the pathogenesis of atherosclerosis. PLoS ONE, 2: e473PubMedGoogle Scholar
  76. 76.
    Mattey D L, Dawes P T, Nixon N B, et al. 2004. Increased levels of antibodies to cytokeratin 18 in patients with rheumatoid arthritis and ischaemic heart disease. Ann Rheum Dis, 63: 420–425.PubMedGoogle Scholar
  77. 77.
    McCormick A L. 2008. Control of apoptosis by human cytomegalovirus. Curr Top Microbiol Immunol, 325: 281–295.PubMedGoogle Scholar
  78. 78.
    Mehraein Y, Lennerz C, Ehlhardt S, et al. 2004. Latent Epstein-Barr virus (EBV) infection and cytomegalovirus (CMV) infection in synovial tissue of autoimmune chronic arthritis determined by RNA-and DNA-in situ hybridization. Mod Pathol, 17: 781–789.PubMedGoogle Scholar
  79. 79.
    Mocarski E S. 2002. Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trends Microbiol, 10:332–339.PubMedGoogle Scholar
  80. 80.
    Mocarski E S. Courcelle, C.T. Cytomegalovirus and their replication, In: Fields’ Virology (Knipe D M, Howley P M, ed.), Lippincott: Philadelphia, p2629–2673.Google Scholar
  81. 81.
    Murphy E, Rigoutsos I, Shibuya T, et al. 2003. Reevaluation of human cytomegalovirus coding potential. Proc Natl Acad Sci USA, 100: 13585–13590.PubMedGoogle Scholar
  82. 82.
    Murphy E, Yu D, Grimwood J, et al. 2003. Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc Natl Acad Sci USA, 100: 14976–14981.PubMedGoogle Scholar
  83. 83.
    Namboodiri A M, Rocca K M, Kuwana M, et al. 2006. Antibodies to human cytomegalovirus protein UL83 in systemic sclerosis. Clin Exp Rheumatol, 24: 176–178.PubMedGoogle Scholar
  84. 84.
    Noyola D E, Valdez-Lopez B H, Hernandez-Salinas A E, et al. 2005. Cytomegalovirus excretion in children attending day-care centers. Arch Med Res, 36: 590–593.PubMedGoogle Scholar
  85. 85.
    Pandey J P. 2004. Immunoglobulin GM genes and IgG antibodies to cytomegalovirus in patients with systemic sclerosis. Clin Exp Rheumatol, 22: S35–7.PubMedGoogle Scholar
  86. 86.
    Pass R F. 2001. Cytomegalovirus, In: Fields’ Virology (Knipe D M, Howley P M ed.), Lippincott: Philadelphia, p2675–2705.Google Scholar
  87. 87.
    Pass R F. 2002. Cytomegalovirus infection. Pediatr Rev, 23: 163–170.PubMedGoogle Scholar
  88. 88.
    Pass R F. 1985. Epidemiology and transmission of cytomegalovirus. J Infect Dis, 152: 243–248.PubMedGoogle Scholar
  89. 89.
    Pawelec G, Gouttefangeas C. 2006. T-cell dysregulation caused by chronic antigenic stress: the role of CMV in immunosenescence? Aging Clin Exp Res, 18: 171–173.PubMedGoogle Scholar
  90. 90.
    Pawelec G, Larbi A. 2008. Immunity and ageing in man: Annual Review 2006/2007. Exp Gerontol, 43: 34–38.PubMedGoogle Scholar
  91. 91.
    Peichl P, Scriba M, Haberhauer G, et al. 1988. Selective binding of rheumatoid factors to antigen structures of cytomegalovirus (CMV). Scand J Rheumatol, Suppl 75: 117–122.Google Scholar
  92. 92.
    Pereira L, Maidji E, McDonagh S, et al. 2005. Insights into viral transmission at the uterine-placental interface. Trends Microbiol, 13: 164–174.PubMedGoogle Scholar
  93. 93.
    Plachter B, Sinzger C, Jahn G. 1996. Cell types involved in replication and distribution of human cytomegalovirus. Adv Virus Res, 46: 195–261.PubMedGoogle Scholar
  94. 94.
    Rafailidis P I, Mourtzoukou E G, Varbobitis I C, et al. 2008. Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. Virol J, 5: 47.PubMedGoogle Scholar
  95. 95.
    Rahbar A, Bostrom L, Soderberg-Naucler C. 2006. Detection of cytotoxic CD13-specific autoantibodies in sera from patients with ulcerative colitis and Crohn’s disease. J Autoimmun, 26: 155–164.PubMedGoogle Scholar
  96. 96.
    Rajagopalan S, Long E O. 2005. Viral evasion of NK-cell activation. Trends Immunol, 26: 403–405.PubMedGoogle Scholar
  97. 97.
    Randolph-Habecker J R, Rahill B, Torok-Storb B, et al. 2002. The expression of the cytomegalovirus chemokine receptor homolog US28 sequesters biologically active CC chemokines and alters IL-8 production. Cytokine, 19: 37–46.PubMedGoogle Scholar
  98. 98.
    Rawlinson W D, Farrell H E, Barrell B G. 1996. Analysis of the complete DNA sequence of murine cytomegalovirus. J Virol, 70: 8833–8849.PubMedGoogle Scholar
  99. 99.
    Reddehase M J, Podlech J, Grzimek N K. 2002. Mouse models of cytomegalovirus latency: overview. J Clin Virol, 25Suppl 2:S23–36.PubMedGoogle Scholar
  100. 100.
    Reeves M B, Lehner P J, Sissons J G, et al. 2005. An in vitro model for the regulation of human cytomegalovirus latency and reactivation in dendritic cells by chromatin remodelling. J Gen Virol, 86: 2949–2954.PubMedGoogle Scholar
  101. 101.
    Reeves M B, MacAry P A, Lehner P J, et al. 2005. Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers. Proc Natl Acad Sci USA, 102: 4140–4145.PubMedGoogle Scholar
  102. 102.
    Reynolds D W, Stagno S, Alford C A. 1981. Chronic congenital and perinatal infections, In: Neonatal pathophysiolaogy and management in the newborn (Avery G B, ed.). Lippincott: Philadelphia, p748–789.Google Scholar
  103. 103.
    Rezania D, Ouban A, Marcet J, et al. 2007. CMV colitis mimicking recurrent inflammatory bowel disease: report of three cases. Am Surg, 73: 58–61.PubMedGoogle Scholar
  104. 104.
    Roback J D. 2002. CMV and blood transfusions. Rev Med Virol, 12: 211–219.PubMedGoogle Scholar
  105. 105.
    Robinson J. 2001. Infectious diseases in schools and child care facilities. Pediatr Rev, 22: 39–46.PubMedGoogle Scholar
  106. 106.
    Ross S A, Boppana S B. 2005. Congenital cytomegalovirus infection: outcome and diagnosis. Semin Pediatr Infect Dis, 16: 44–49.PubMedGoogle Scholar
  107. 107.
    Sansoni P, Vescovini R, Fagnoni F, et al. 2008. The immune system in extreme longevity. Exp Gerontol, 43: 61–65.PubMedGoogle Scholar
  108. 108.
    Scalzo A A, Corbett A J, Rawlinson W D, et al. 2007. The interplay between host and viral factors in shaping the outcome of cytomegalovirus infection. Immunol Cell Biol, 85: 46–54.PubMedGoogle Scholar
  109. 109.
    Schleiss M R. 2003. Vertically transmitted herpesvirus infections. Herpes, 10:4–11.PubMedGoogle Scholar
  110. 110.
    Sekigawa I, Nawata M, Seta N, et al. 2002. Cytomegalovirus infection in patients with systemic lupus erythematosus. Clin Exp Rheumatol, 20: 559–564.PubMedGoogle Scholar
  111. 111.
    Sinclair J. 2008. Human cytomegalovirus: Latency and reactivation in the myeloid lineage. J Clin Virol, 41: 180–185.PubMedGoogle Scholar
  112. 112.
    Sinclair J, Sissons P. 2006. Latency and reactivation of human cytomegalovirus. J Gen Virol, 87: 1763–1779.PubMedGoogle Scholar
  113. 113.
    Sinzger C, Jahn G. 1996. Human cytomegalovirus cell tropism and pathogenesis. Intervirology, 39: 302–319.PubMedGoogle Scholar
  114. 114.
    Sissons J G, Bain M, Wills M R. 2002. Latency and reactivation of human cytomegalovirus. J Infect, 44: 73–77.PubMedGoogle Scholar
  115. 115.
    Skaletskaya A, Bartle L M, Chittenden T, et al. 2001. A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation. Proc Natl Acad Sci USA, 98: 7829–7834.PubMedGoogle Scholar
  116. 116.
    Smith H R, Heusel J W, Mehta I K, et al. 2002. Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc Natl Acad Sci USA, 99: 8826–8831.PubMedGoogle Scholar
  117. 117.
    Smith M G. 1956. Propagation in tissue cultures of a cytopathogenic virus from human salivary gland virus (SGV) disease. Proc Soc Exp Biol Med, 92: 424–440.PubMedGoogle Scholar
  118. 118.
    Smith M G. 1954. Propagation of salivary gland virus of the mouse in tissue cultures. Proc Soc Exp Biol Med, 86: 435–440.PubMedGoogle Scholar
  119. 119.
    Soderberg-Naucler C, Fish K N, Nelson J A. 1997. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell, 91: 119–126.PubMedGoogle Scholar
  120. 120.
    Soderberg-Naucler C, Streblow D N, Fish K N, et al. 2001. Reactivation of latent human cytomegalovirus in CD14(+) monocytes is differentiation dependent. J Virol, 75: 7543–7554.PubMedGoogle Scholar
  121. 121.
    Stahl H D, Hubner B, Seidl B, et al. 2000. Detection of multiple viral DNA species in synovial tissue and fluid of patients with early arthritis. Ann Rheum Dis, 59: 342–346.PubMedGoogle Scholar
  122. 122.
    Staras S A, Dollard S C, Radford K W, et al. 2006. Seroprevalence of cytomegalovirus infection in the United States, 1988–1994. Clin Infect Dis, 43: 1143–1151.PubMedGoogle Scholar
  123. 123.
    Streblow D N, Dumortier J, Moses A V, et al. 2008. Mechanisms of cytomegalovirus-accelerated vascular disease: induction of paracrine factors that promote angiogenesis and wound healing. Curr Top Microbiol Immunol, 325: 397–415.PubMedGoogle Scholar
  124. 124.
    Sutherland C L, Chalupny N J, Schooley K, et al. 2002. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J Immunol, 168: 671–679.PubMedGoogle Scholar
  125. 125.
    Tang Q, Maul G G. 2006. Mouse cytomegalovirus crosses the species barrier with help from a few human cytomegalovirus proteins. J Virol, 80: 7510–7521.PubMedGoogle Scholar
  126. 126.
    Terhune S, Torigoi E, Moorman N, et al. 2007. Human cytomegalovirus UL38 protein blocks apoptosis. J Virol, 81: 3109–3123.PubMedGoogle Scholar
  127. 127.
    Thompson J N. 1994. The Coevolutionary Process. University of Chicago Press: Chicago, USA.Google Scholar
  128. 128.
    Tsuchiya N, Murayama T, Yoshinoya S, et al. 1993. Antibodies to human cytomegalovirus 65-kilodalton Fc binding protein in rheumatoid arthritis: idiotypic mimicry hypothesis of rheumatoid factor production. Autoimmunity, 15: 39–48.PubMedGoogle Scholar
  129. 129.
    Vancikova Z, Dvorak P. 2001. Cytomegalovirus infection in immunocompetent and immunocompromised individuals—a review. Curr Drug Targets Immune Endocr Metabol Disord, 1: 179–187.PubMedGoogle Scholar
  130. 130.
    Vasto S, Colonna-Romano G, Larbi A, et al. 2007. Role of persistent CMV infection in configuring T cell immunity in the elderly. Immun Ageing, 4: 2.PubMedGoogle Scholar
  131. 131.
    Verdonk R C, Haagsma E B, Van Den Berg A P, et al. 2006. Inflammatory bowel disease after liver transplantation: a role for cytomegalovirus infection. Scand J Gastroenterol, 41: 205–211.PubMedGoogle Scholar
  132. 132.
    Vescovini R, Biasini C, Fagnoni F F, et al. 2007. Massive load of functional effector CD4+ and CD8+ T cells against cytomegalovirus in very old subjects. J Immunol, 179: 4283–4291.PubMedGoogle Scholar
  133. 133.
    Vink C, Beuken E, Bruggeman C A. 2000. Complete DNA sequence of the rat cytomegalovirus genome. J Virol, 74: 7656–7665.PubMedGoogle Scholar
  134. 134.
    Vitale M, Castriconi R, Parolini S, et al. 1999. The leukocyte Ig-like receptor (LIR)-1 for the cytomegalovirus UL18 protein displays a broad specificity for different HLA class I alleles: analysis of LIR-1 + NK cell clones. Int Immunol, 11: 29–35.PubMedGoogle Scholar
  135. 135.
    Voigt S, Mesci A, Ettinger J, et al. 2007. Cytomegalovirus evasion of innate immunity by subversion of the NKR-P1B:Clr-b missing-self axis. Immunity, 26: 617–627.PubMedGoogle Scholar
  136. 136.
    Wagner C S, Ljunggren H G, Achour A. 2008. Immune modulation by the human cytomegalovirus-encoded molecule UL18, a mystery yet to be solved. J Immunol, 180: 19–24.PubMedGoogle Scholar
  137. 137.
    Waller E C, Day E, Sissons J G, et al. 2008. Dynamics of T cell memory in human cytomegalovirus infection. Med Microbiol Immunol, 197: 83–96.PubMedGoogle Scholar
  138. 138.
    Weller T H, Hanshaw J B, Scott D E. 1960. Serological differentiation of viruses responsible for cytomegalic inclusion disease. Virology, 12: 130–132.PubMedGoogle Scholar
  139. 139.
    Wiertz E J, Jones T R, Sun L, et al. 1996. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell, 84: 769–779.PubMedGoogle Scholar
  140. 140.
    Woolhouse M E, Webster J P, Domingo E, et al. 2002. Biological and biomedical implications of the coevolution of pathogens and their hosts. Nat Genet, 32: 569–577.PubMedGoogle Scholar
  141. 141.
    Yi L, Lin J Y, Gao Y, et al. 2008. Detection of human cytomegalovirus in the atherosclerotic cerebral arteries in han population in china. Acta Virol, 52: 99–106.PubMedGoogle Scholar
  142. 142.
    Ziemann M, Krueger S, Maier A B, et al. 2007. High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion. Transfusion, 47: 1972–1983.PubMedGoogle Scholar

Copyright information

© Wuhan Institute of Virology, CAS and Springer-Verlag GmbH 2008

Authors and Affiliations

  1. 1.Division of Infectious Diseases, School of Public HealthUniversity of CaliforniaBerkeleyUSA

Personalised recommendations